The High-Risk Type 1 Diabetes HLA-DR and HLA-DQ Polymorphisms Are Differentially Associated With Growth and IGF-I Levels in Infancy: The Cambridge Baby Growth Study.
Diabetes care 2020 ; 44: 1852-1859.
DOI : 10.2337/dc20-2820
PubMed ID : 34172490
This study explored the link between HLA polymorphisms that predispose to type 1 diabetes and birth size, infancy growth, and/or circulating IGF-I in a general population-based birth cohort.
The Cambridge Baby Growth Study is a prospective observational birth cohort study that recruited 2,229 newborns for follow-up in infancy. Of these, 612 children had DNA available for genotyping single nucleotide polymorphisms in the HLA region that capture the highest risk of type 1 diabetes: rs17426593 for , rs2187668 for , and rs7454108 for . Multivariate linear regression models at critical ages (cross-sectional) and mixed-effects models (longitudinal) were performed under additive genetic effects to test for associations between HLA polymorphisms and infancy weight, length, skinfold thickness (indicator of adiposity), and concentrations of IGF-I and IGF-binding protein-3 (IGFBP-3).
In longitudinal models, the minor allele of rs2187668 tagging was associated with faster linear growth ( = 0.007), which was more pronounced in boys ( = 3 × 10) than girls ( = 0.07), and was also associated with increasing IGF-I ( = 0.002) and IGFBP-3 ( = 0.003) concentrations in infancy. Cross-sectionally, the minor alleles of rs7454108 tagging and rs17426593 tagging were associated with lower IGF-I concentrations at age 12 months ( = 0.003) and greater skinfold thickness at age 24 months ( = 0.003), respectively.
The variable associations of , , and alleles with growth measures and IGF-I levels in infants from the general population could explain the heterogeneous growth trajectories observed in genetically at-risk cohorts. These findings could suggest distinct mechanisms involving endocrine pathways related to the HLA-conferred type 1 diabetes risk.